Clinomic's Mona: Revolutionizing ICU Care with €23 Million Boost
April 16, 2025, 3:31 am
Location: Germany, North Rhine-Westphalia, Alsdorf
Employees: 51-200
Founded date: 2019
Total raised: $26.13M
In the heart of Aachen, Germany, a health tech revolution is brewing. Clinomic, a startup founded by intensive care physicians, has just secured €23 million in Series B funding. This financial windfall is set to supercharge the deployment of its innovative ICU assistant, Mona. The goal? To transform the landscape of critical care.
Clinomic’s journey began in 2019, when a group of doctors from RWTH Aachen University Hospital recognized a pressing issue in intensive care units (ICUs). The sheer volume of data generated in these high-stakes environments was overwhelming. Physicians found themselves drowning in information, leaving little time for actual patient care. They envisioned a solution—a digital assistant that could streamline workflows and enhance patient outcomes. Thus, Mona was born.
Mona, short for Medical On-Site Assistant, is not just another tech gadget. It’s a comprehensive platform that integrates artificial intelligence, speech recognition, and telemedicine. Imagine a digital Swiss Army knife for the ICU. It consolidates patient information from various departments, analyzes it in real-time, and presents actionable insights to healthcare professionals. This allows doctors to focus on what truly matters: their patients.
The recent funding round was co-led by DeepTech & Climate Fonds (DTCF) and a private family office, bringing Clinomic’s total funding to €44.8 million. This financial backing is a testament to the potential impact of Mona. With the new capital, Clinomic plans to expand its international footprint, enhance its AI capabilities, and deepen its influence on critical care delivery.
Clinomic’s CEO, Georg Griesemann, expressed excitement about the support from investors who share their vision. The company is tackling some of the most pressing challenges in intensive care today, including staff shortages and information overload. Mona aims to bridge the digitization gap, making critical data accessible and actionable.
The platform has already made waves in Europe, being implemented in over 40 hospitals across eight EU countries. Now, Clinomic is setting its sights on the U.S. market, seeking FDA approval to expand its reach. This move could redefine how ICUs operate in one of the world’s largest healthcare markets.
Mona’s capabilities are impressive. It responds to voice commands, reducing the need for physical interaction with devices. This feature is particularly valuable in an ICU setting, where every second counts. Additionally, Mona’s predictive analytics can flag critical changes in patient data, allowing for timely interventions. It’s like having a vigilant guardian watching over patients, ready to alert healthcare providers at the first sign of trouble.
The impact of Mona extends beyond patient care. By optimizing clinical and administrative workflows, the platform also aims to reduce healthcare costs. In a world where every dollar counts, this dual focus on quality and efficiency is crucial. Clinomic is not just improving patient outcomes; it’s setting a new standard for digital intensive care.
The investment from DTCF underscores the belief in Clinomic’s mission. The firm recognized the potential of Mona to address critical healthcare challenges with measurable results. This support is not just financial; it’s a partnership in innovation. Together, they are redefining what’s possible in intensive care.
As the healthcare landscape continues to evolve, the need for digital solutions becomes increasingly clear. Clinomic’s Mona is at the forefront of this transformation. It embodies the future of healthcare—data-driven, efficient, and patient-centered. The integration of AI into critical care is not just a trend; it’s a necessity.
The journey ahead is promising. With the new funding, Clinomic is poised to accelerate its growth and expand its impact. The vision of a modern, data-driven ICU is within reach. As Mona continues to evolve, it will empower clinicians and improve lives.
In a world where healthcare is often reactive, Mona represents a proactive approach. It’s about anticipating needs, improving workflows, and ultimately enhancing patient care. The challenges in intensive care are significant, but with innovative solutions like Mona, there is hope.
Clinomic’s story is one of vision, innovation, and determination. The founders, driven by their experiences as physicians, are committed to making a difference. They understand the stakes and are working tirelessly to bridge the gaps in critical care.
As we look to the future, the importance of technology in healthcare cannot be overstated. Clinomic is leading the charge, proving that with the right tools, we can transform the way we care for patients. The €23 million funding is not just a financial boost; it’s a vote of confidence in a brighter future for intensive care.
In conclusion, Clinomic’s Mona is more than a product; it’s a revolution in ICU care. With its innovative approach and strong backing, the company is set to change the game. The future of healthcare is here, and it’s powered by technology.
Clinomic’s journey began in 2019, when a group of doctors from RWTH Aachen University Hospital recognized a pressing issue in intensive care units (ICUs). The sheer volume of data generated in these high-stakes environments was overwhelming. Physicians found themselves drowning in information, leaving little time for actual patient care. They envisioned a solution—a digital assistant that could streamline workflows and enhance patient outcomes. Thus, Mona was born.
Mona, short for Medical On-Site Assistant, is not just another tech gadget. It’s a comprehensive platform that integrates artificial intelligence, speech recognition, and telemedicine. Imagine a digital Swiss Army knife for the ICU. It consolidates patient information from various departments, analyzes it in real-time, and presents actionable insights to healthcare professionals. This allows doctors to focus on what truly matters: their patients.
The recent funding round was co-led by DeepTech & Climate Fonds (DTCF) and a private family office, bringing Clinomic’s total funding to €44.8 million. This financial backing is a testament to the potential impact of Mona. With the new capital, Clinomic plans to expand its international footprint, enhance its AI capabilities, and deepen its influence on critical care delivery.
Clinomic’s CEO, Georg Griesemann, expressed excitement about the support from investors who share their vision. The company is tackling some of the most pressing challenges in intensive care today, including staff shortages and information overload. Mona aims to bridge the digitization gap, making critical data accessible and actionable.
The platform has already made waves in Europe, being implemented in over 40 hospitals across eight EU countries. Now, Clinomic is setting its sights on the U.S. market, seeking FDA approval to expand its reach. This move could redefine how ICUs operate in one of the world’s largest healthcare markets.
Mona’s capabilities are impressive. It responds to voice commands, reducing the need for physical interaction with devices. This feature is particularly valuable in an ICU setting, where every second counts. Additionally, Mona’s predictive analytics can flag critical changes in patient data, allowing for timely interventions. It’s like having a vigilant guardian watching over patients, ready to alert healthcare providers at the first sign of trouble.
The impact of Mona extends beyond patient care. By optimizing clinical and administrative workflows, the platform also aims to reduce healthcare costs. In a world where every dollar counts, this dual focus on quality and efficiency is crucial. Clinomic is not just improving patient outcomes; it’s setting a new standard for digital intensive care.
The investment from DTCF underscores the belief in Clinomic’s mission. The firm recognized the potential of Mona to address critical healthcare challenges with measurable results. This support is not just financial; it’s a partnership in innovation. Together, they are redefining what’s possible in intensive care.
As the healthcare landscape continues to evolve, the need for digital solutions becomes increasingly clear. Clinomic’s Mona is at the forefront of this transformation. It embodies the future of healthcare—data-driven, efficient, and patient-centered. The integration of AI into critical care is not just a trend; it’s a necessity.
The journey ahead is promising. With the new funding, Clinomic is poised to accelerate its growth and expand its impact. The vision of a modern, data-driven ICU is within reach. As Mona continues to evolve, it will empower clinicians and improve lives.
In a world where healthcare is often reactive, Mona represents a proactive approach. It’s about anticipating needs, improving workflows, and ultimately enhancing patient care. The challenges in intensive care are significant, but with innovative solutions like Mona, there is hope.
Clinomic’s story is one of vision, innovation, and determination. The founders, driven by their experiences as physicians, are committed to making a difference. They understand the stakes and are working tirelessly to bridge the gaps in critical care.
As we look to the future, the importance of technology in healthcare cannot be overstated. Clinomic is leading the charge, proving that with the right tools, we can transform the way we care for patients. The €23 million funding is not just a financial boost; it’s a vote of confidence in a brighter future for intensive care.
In conclusion, Clinomic’s Mona is more than a product; it’s a revolution in ICU care. With its innovative approach and strong backing, the company is set to change the game. The future of healthcare is here, and it’s powered by technology.